SCHEMBL1007283

SCHEMBL1007283

CCc1nn(Cc2ccc(C(=O)O)cc2)c2c1CCCC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
RAB9A P51151 1/20 0.45
ALDH1A1 P00352 2/20 0.44
FABP4 P15090 1/20 0.44
SLC22A12 Q96S37 2/20 0.42
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
THRB P10828 1/20 0.41
NR4A1 P22736 1/20 0.41
APEX1 P27695 1/20 0.41
APOBEC3A P31941 1/20 0.41
RECQL P46063 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HIF1A Q16665 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1007995 0.89 RARB (0.47) KDM4ETDP1L3MBTL1RAB9AALDH1A1
SCHEMBL1007656 0.86 RAB9A (0.51) KDM4ERAB9AALDH1A1MAPTMEN1
SCHEMBL1007553 0.85 HRH3 (0.48) KDM4EL3MBTL1RAB9AALDH1A1MAPT
SCHEMBL1007634 0.81 PTGER4 (0.44) KDM4ETDP1L3MBTL1RAB9AALDH1A1
SCHEMBL13521117 0.79 LMNA (0.62) ALDH1A1MAPTPOLBGAATHRB
SCHEMBL1005669 0.76 GAA (0.48) RAB9AMEN1POLBGAAKMT2A
SCHEMBL1008169 0.76 HPGD (0.47) KDM4EL3MBTL1RAB9AALDH1A1MEN1
SCHEMBL8430774 0.74 MEN1 (0.47) RAB9AFABP4MEN1KMT2ASMN1; SMN2
SCHEMBL5806383 0.74 FABP4 (0.49) RAB9AALDH1A1FABP4MAPTGAA
SCHEMBL182893 0.73 FABP4 (0.49) FABP4MEN1POLBGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
WO-2009119088-A1 HETEROCYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118236-A1 HETEROCYCLIC COMPOUND GRIN1, GRM1, GRIK1 KDM4E 3157/4885TDP1 3371/4885L3MBTL1 4436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.